{
  "pmcid": "3085934",
  "sha256": "cddd5c2ec544a2c9372d5030bf5c5042fd933c70fc986c7a73a0636c3f0d2e26",
  "timestamp_utc": "2025-11-09T15:51:20.743540+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.153512616201859,
    "reading_ease": 18.425611996458628,
    "word_count": 251
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Purpose: Surgical resection provides the only possibility of cure for pancreas cancer."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A single institution phase II study of 60 patients with resected pancreatic adenocarcinoma was performed."
      },
      "Participants": {
        "score": 1,
        "evidence": "60 patients with resected pancreatic adenocarcinoma"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Each immunotherapy treatment consisted of a total of 5 × 10 8 GM-CSF-secreting cells distributed equally among 3 lymph node regions."
      },
      "Objective": {
        "score": 1,
        "evidence": "We tested the safety and efficacy of a granulocyte-macrophage colony-stimulating factor (GM-CSF)-based immunotherapy administered in patients with resected pancreatic adenocarcinoma."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was disease free survival and secondary endpoints were overall survival and toxicity, and the induction of mesothelin-specific T cell responses."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A single institution phase II study of 60 patients"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The median disease-free survival is 17.3 months (95% CI, 14.6–22.8) with median survival of 24.8 months (95% CI, 21.2–31.6)."
      },
      "Harms": {
        "score": 1,
        "evidence": "The administration of immunotherapy was well tolerated."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 12,
    "max_score": 25
  }
}